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Abstract 
The resistance of bacteria against the use of conventional antibiotics has become a serious threat to public health 
and considering the associated side effect with antibiotics; new strategies to find and develop new molecules with 
novel modes of action has received grate attention in recent years. In this study, when the antibacterial potential of an 
acidic protein—NN-XIb-PLA2 (Naja naja venom phospholipase A2 fraction—XIb) of Naja naja venom was evaluated, it 
showed significant bactericidal action against the human pathogenic strains tested. It inhibited more effectively the 
gram positive bacteria like Staphylococcus aureus and Bacillus subtilis, when compared to gram negative bacteria like 
Escherichia coli, Vibrio cholerae, Klebsiell pneumoniae and Salmonella paratyphi. It inhibited the bacterial growth, with a 
MIC values ranging from 17 to 20 µg/ml. It was interesting to observe that NN-XIb-PLA2 showed comparable antibac-
terial activity to the used standards antibiotics. It was found that their was a strong correlation between PLA2 activi-
ties, hemolytic and antibacterial activity. Furthermore, it is found that in the presence of p-bromophenacyl bromide 
(p-BPB), there is a significant decrease in enzymatic activity and associated antibacterial activities, suggesting that a 
strong association exists between catalytic activity and antimicrobial effects, which thereby destabilize the membrane 
bilayer. These studies encourage further in dept study on molecular mechanisms of bactericidal properties of NN-XIb-
PLA2 and thereby help in development of this protein into a possible therapeutic lead molecule for treating bacterial 
infections.
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Background
Worldwide increase in resistance of bacteria for the use 
of antibiotics and the undesirable side effects associ-
ated with it has become a serious public health problem 
(Norrby et al. 2005; Choudhury et al. 2012; Echols 2012; 
Ghafur 2013). This resistance to conventional antibiotic 
has prompted an intensive search for new therapeutic 
agents from diverse sources, including of animal origin 
(Zasloff 2002). Proteins/peptides with potent antimicro-
bial activity from different secretary organisms, include 
snake (venom) have been identified (Zasloff 2002; Samy 
et  al. 2012). Snake venom, particularly of crotalidae 
venoms, is a rich source for discovery and development 
of novel microbicidal agents (Perumal Samy et  al. 2006; 
Samy et  al. 2012). Among various components of snake 
venom, phospoholipase A2 (PLA2) enzyme apart from 
the catalytic activity of hydrolyzing the sn-2 ester bond 
of glycerophospholipids, exhibits diverse biological/phar-
macological activities (Kini 1997; Gutiérrez and Lomonte 
2013). The diverse arrays of biological actions are either 
known to be dependent or independent of catalytic activ-
ity (Kini 1997; Gutiérrez and Lomonte 2013). svPLA2s are 
also reported as antimicrobial agents and are emphasized 
for its development into a therapeutic drug for treating 
infectious diseases (Perumal Samy et al. 2006; Samy et al. 
2012). Crotapotin, a secretory phospholipase A2 of the 
Crotalus durissus terrificus venom, shows antibacterial 
activity (Soares et al. 2001a, b) as well as antiviral activ-
ity against the human immunodeficiency virus (Toyama 
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et  al. 2003; Sampaio et  al. 2003). An acidic PLA2, both 
Asp49 and Lys49 PLA2 homologue (Paramo et al. 1998; 
Vargas et al. 2012), have previously been shown to pos-
sess bactericidal activity (Soares et  al. 2001a, b). A cati-
onic protein of inland taipan (Oxyuranus microlepidotus) 
venom is demonstrated to selectively and dose-depend-
ently kill gram-positive bacteria through membrane dis-
ruption (Nair et  al. 2007). Perumal Samy et  al. (2010), 
recently reported a saw-scaled viper venom phospholi-
pase A2 with novel bactericidal and membrane damag-
ing activities. Thus svPLA2 are demonstrated to be very 
attractive to be developed as microbicidal therapeu-
tic agents because of their biochemical diversity, broad 
spectrum of activity against enveloped bacteria, fungi, 
viruses, protozoa, and parasites (Pereira 2006; Perumal 
Samy et al. 2006; Samy et al. 2012).
Despite the potential therapeutic application of svP-
LA2s as antimicrobial agents (Pereira 2006; Perumal 
Samy et al. 2006; Samy et al. 2012), very few svPLA2s with 
microbicidal/antimicrobial activities have been char-
acterized for their mechanism of action (Pereira 2006; 
Samy et  al. 2012; de Oliveira Junior et  al. 2013). Indian 
Cobra (Naja naja) species is a widely distributed snake 
that is responsible for potent toxic and lethal effects 
(Mukherjee and Maity 2002; Shashidharamurthy et  al. 
2002, 2010; Dhananjaya et al. 2006; Hiremath et al. 2013). 
Although several reports exists on its various biological 
effects (Mukherjee and Maity 2002; Shashidharamurthy 
et al. 2002, 2010; Dhananjaya et al. 2006; Hiremath et al. 
2013). However, there are very limited reports available 
on the microbicidal activities exhibited by PLA2s from 
Indian Cobra venom (Sudarshan and Dhananjaya 2015). 
An acidic PLA2—NN-XIb-PLA2 (Naja naja venom phos-
pholipase A2 fraction—XIb) isolated from Naja naja 
venom (Rudrammaji and Gowda 1998) is reported for 
various biological effects (Rudrammaji and Gowda 1998), 
however studies on its therapeutic properties particulary 
as an anti-bacterial agent has not been clearly evaluated. 
Therefore, in this study we evaluate the antibacterial 
potential of NN-XIb-PLA2 and its possible mechanism 
of action. Further, this study exemplifies the therapeutic 
utility of NN-XIb-PLA2 as an antimicrobial drug/agent.
Materials and methods
Venom of Naja naja was purchased from Irula Co-oper-
ative Society Ltd., Chennai, India. Agar, beef extract, 
yeast extract and peptone were purchased from Hi Media 
Private Ltd., Mumbai, India. p-bromophenacyl bromide 
(p-BPB) and other chemicals used were of all analyti-
cal grades purchased from Sigma Chemicals Ltd. USA. 
Authentic pure clinical isolated cultures of human path-
ogenic bacteria; Staphylococcus aureus, Bacillus subti-
lis, Escherichia coli, Salmonella typhi, Vibrio cholerae, 
Klebsiella pneumoniae and Salmonella paratyphi were 
obtained from the Microbiology Department, Adichun-
chanagiri Institute of Medical Sciences (AIMS), B.G. 
Nagara, Karnataka, India. These are all human pathogens 
that have developed some resistance to common anti-
biotics particularly in the in the clinical environment. 
Bacteria were multiplied in nutrient agar at 36 ±  2  °C. 
After 2 days, cultures were harvested and prepared at a 
final concentration of 1 × 108 cfu/ml and used for in vitro 
inhibition assay. All other chemicals used were of analyti-
cal grade.
Isolation of NN‑XIb‑PLA2 and chemical modification 
by p‑bromophenacyl bromide
NN-XIb-PLA2 from the venom Naja naja (Southern 
region) was purified up to homogeneity as described pre-
viously by the method of Rudrammaji and Gowda (1998). 
The protein concentration was estimated by Lowry’s 
method. Chemical modification of PLA2 by p-BPB was 
carried out as described by Condrea et  al. (1981) One 
hundred microliters of 40  mM p-BPB in acetone were 
added to 3  ml of PLA2 solution (0.5  mg/ml, in 0.05  M 
Tris–HCl buffer, pH 7.5). The reaction was allowed to 
proceed for 40 min, and then acidified with glacial acetic 
acid to pH 4.0 to stop the reaction. Excess of reagent was 
removed by dialysing against 0.05 M Tris–HCl buffer pH 
7.5.
Phospholipase A2 activity
The Phospholipase A2 assay was carried out according 
to the method as described by Bhat and Gowda (1989). 
Phosphatidyl choline was diluted with petroleum ether 
(60–80  °C) to get a concentration of 1000  nmol/50  ml. 
The reaction mixture containing NN-XIb-PLA2 (6  μg) 
was made up to 680 ml with water. To the reaction mix-
ture, 200 μl of ether, 100 μl of Tris–HCl buffer (0.05 M, 
pH 7.5), and 20 μl of CaCl2 (0.4 M) was added. The total 
reaction mixture was incubated at 37 °C for 60 min. After 
incubation, 0.5  ml of Doles mixture (Isopropanol: Pet 
ether: 1NH2SO4, 40:10:1) was added, mixed and centri-
fuged at 1000 rpm for 3 min. To the organic phase 0.5 ml 
of CHCl3: Pet ether (1:5) was added, mixed and centri-
fuged at 1000 rpm for 3 min. To the upper phase cobalt 
reagent [1.35 vol. of Triethanolamine made up to 10 ml 
with solution A (6 g of CO(NO3)2·6H2O + 0.8 ml glacial 
acetic acid) and 7  ml of solution B (Saturated Na2SO4)] 
was added, mixed and centrifuged 1000  rpm for 3  min. 
The upper organic phase was carefully transferred and 
0.75 ml of α-nitroso-β-naphthol reagent (0.4 % α-nitroso-
β-naphthol in 96 % ethanol) was added. The intensity of 
the orange colour is directly proportional to the amount 
of cobalt present. After 30  min 2  ml of ethanol was 
added to dilute the contents and absorbance was read at 
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540 nm. The amount of free fatty acid released was esti-
mated using standard linolenic acid curve. The enzyme 
activity was expressed as nmoles of fatty acid released/
min/mg of protein.
For inhibition studies, NN-XIb-PLA2 (6  μg) was pre-
incubated with or without different concentration of p-
BPB (1–6 μm) at 37 °C for 15 min. Appropriate controls 
were carried and further experiments were carried out as 
described above. The inhibition is expressed as percent-
age taking activity of venom alone as 100 %.
Haemolytic activity assay
Haemolytic (direct/indirect) activity of isolated NN-
XIb-PLA2 was determined according to the method of 
Boman and Kaletta (1957), using packed human eryth-
rocytes (blood group A). The direct and indirect haemo-
lytic assays were carried out using washed erythrocytes. 
For the direct haemolytic assay, packed erythrocytes 
(1  ml) were suspended in nine volumes of phosphate-
buffered saline (PBS), which formed the stock. The stock 
(1 ml) was incubated with various concentrations of iso-
lated NN-XIb-PLA2 (0–5 µg) for 30 min at 37 °C. For the 
indirect haemolytic assay, stock was prepared by mixing 
packed erythrocytes (1  ml), egg yolk (1  ml) and phos-
phate-buffered saline (8 ml). One millilitre of suspension 
from stock was incubated with various concentrations of 
isolated NN-XIb-PLA2 (0–3 µg) for 30 min at 37 °C. The 
reaction was terminated by adding 10 ml of ice-cold PBS 
and then centrifuged at 4  °C and 800  g. The amount of 
haemoglobin released in the supernatant was measured 
at 540 nm. One millilitre of stock erythrocytes with 10 ml 
ice-cold PBS alone was considered as 0 % lysis.
For inhibition studies, NN-XIb-PLA2 (3  μg) was pre-
incubated with or without different concentration of p-
BPB (1–6 μM) at 37 °C for 15 min. Appropriate controls 
were carried and further experiments were carried out as 
described above. The inhibition is expressed as percent-
age taking activity of venom alone as 100 %.
Bactericidal activity of NN‑XIb‑PLA2
Bactericidal activity was evaluated by the well diffusion 
method on nutrient agar medium (Forbes et  al. 1990). 
This was confirmed by the inhibitory effect on bacterial 
growth as reflected by the inhibition zone, compared to 
that of known antibiotics like Gentamycin (G); Chloram-
phenicol (Cp) and Streptomycin (Sm) at 30  µg/ml. The 
sterile nutrient agar medium (20 ml) in petri dishes was 
uniformly smeared using sterile cotton swabs with test 
pure cultures of human pathogenic bacteria S. aureus, B. 
subtilis, E. coli, S. typhi, V. cholerae, K. pneumoniae and S. 
paratyphi. The nutrient agar media was prepared by dis-
solving 0.3 % beef extract, 0.3 % yeast extract, 0.5 % pep-
tone, 0.5 % NaCl and 1.5 % agar in 1: l of distilled water. 
The wells of 5  mm diameter were made using a sterile 
cork borer in each petri dish and the isolated NN-XIb-
PLA2 (0–6  µg) pre-incubated independently with or 
without p-BPB (15 μM) were added; a blank well loaded 
without test compound was regarded as control. For 
each treatment, 10 replicates were prepared. The plates 
were incubated at 37  °C for 24 h and the resulting zone 
of inhibition was measured by comparing control and the 
standard antibiotics.
For inhibition studies, NN-XIb-PLA2 (6 μg) was prein-
cubated with or without different concentration of p-BPB 
(1–6  μM) at 37  °C for 15  min and antimicrobial activ-
ity was carried out as described above with appropriate 
controls. The inhibition is expressed as percentage taking 
activity of venom alone as 100 %.
Determination of minimum inhibitory concentration (MIC)
The minimum inhibitory concentration of the isolated 
NN-XIb-PLA2 and the antibiotics used were determined 
by serial dilution in the nutrient agar, with concentra-
tions ranging from 2 to 20  µg/ml. The inoculum was 
prepared from fresh overnight broth culture in nutrient 
broth and plates were incubated for 24 h at 37  °C. MIC 
was recorded as the lowest NN-XIb-PLA2 and the anti-
biotics concentration demonstrating no visible growth in 
the broth (Prescot et al. 1996).
Statistical analysis
Statistical analysis was done using SPSS (Windows ver-
sion 10.0.1; SPSS Inc., Chicago, IL) using a one-way 
student’s t test; p  <  0.05 was considered as statistically 
significant, when comparing with relevant controls. All 
results refer to mean ± SD.
Results and discussion
Snake venom PLA2s, apart from their well known diverse 
biological/pharmacological function are also known to 
act as antibacterial agents (Samy et al. 2012; de Oliveira 
Junior et al. 2013). The acidic PLA2—NN-XIb-PLA2 iso-
lated from Naja naja venom (Rudrammaji and Gowda 
1998) is reported for various biological effects (Rudram-
maji and Gowda 1998). In this study, when evaluated 
for antibacterial activity on different microbial species, 
it was observed that NN-XIb-PLA2 (0–6  µg/ml) dose-
dependently (Fig.  1a, b) had a broad spectrum of very 
significant antibacterial activity by producing a clear 
zone of inhibition in the range of 17 ±  2–20 ±  3  mm, 
which was comparable to the standards used like genta-
mycin, chlorophenicol and streptomycin (which were in 
the range of 16–20 mm) (Table 1). When NN-XIb-PLA2 
was tested, using the agar dilution assay for determin-
ing the minimum inhibitory concentration (MIC), it was 
observed that it inhibited bacterial growth, with MIC 
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values ranging from 19 to 26 µg/ml. It was interesting to 
observe that NN-XIb-PLA2 showed comparable MIC val-
ues with standard antibiotics, which ranged from 11.2 to 
20  µg/ml (Table  2). Thus, NN-XIb-PLA2 is as potent as 
standard antibiotics in inhibiting the growth of bacterial 
strains (Fig. 2).
It is usually observed that there is a strong correlation 
between PLA2, hemolytic and antibacterial activities 
(Samy et al. 2012; de Oliveira Junior et al. 2013; Perumal 
Samy et al. 2007). When evaluated, it was found that NN-
XIb-PLA2, dose dependently hemolysed the blood cells 
and at 3  µg/ml concentration it showed 100  % hemoly-
sis (Fig.  1). From these data it may be concluded that 
the antibacterial effects of NN-XIb-PLA2 is dependent 
upon catalytic activity i.e. enzymatic membrane degra-
dation effect that is usually observed in svPLA2s (Samy 
et  al. 2012; Buckland and Wilton 2000; Sudarshan and 
Dhananjaya 2015). Also, the correlation between PLA2, 
hemolytic and antibacterial activities, exemplifies that 
the catalytically activity of PLA2 is principally involved 
in bactericidal/antibacterial activities (Samy et  al. 2012; 
de Oliveira Junior et al. 2013; Perumal Samy et al. 2010; 
Sudarshan and Dhananjaya 2015), however other mecha-
nism can not be completely ruled out. Bothrops asper 
(also classified within group IIA) snake venom PLA2 
was shown to directly kill both gram-positive and gram-
negative bacteria (Paramo et  al. 1998). Further, it was 
observed that one of the toxin of B. asper i.e., myotoxin 
II, a catalytically-inactive Lys49 PLA2 exhibited bacte-
ricidal mechanism, independent of its catalytic activity 
(Paramo et al. 1998; Samy et al. 2012; de Oliveira Junior 
et al. 2013). Further studies showed that a short sequence 
of the protein, i.e., corresponding to residues 115–129 
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Fig. 1 Dose-dependent bactericidal activity of NN-XIb-PLA2 a 
bactericidal activity against S. aureus, B. subtiles, E. coli, S. typhi, b V. 
cholerae, K. pneumoniae, S. paratyphi. The diameter of the clear zone 
was measured and plotted after subtracting the diameter of the well 
(5 mm). Results are mean ± SD for three independent assays each 
performed in triplicate
Table 1 Antibacterial activity of  NN-XIb-PLA2 and  stand-
ard antibiotics
The results are mean SD (n = 6)
G gentamycin, Cp chloramphenicol, Sm streptomycin
Microorganisms Diameter of inhibition zone (mm)
NN‑PL‑XIb G Cp Sm
Gram positive
 Staphylococcus aureus 18 ± 2 18 ± 1 23 ± 2 26 ± 2
 Bacillus subtilis 16 ± 3 18 ± 2 19 ± 2 28 ± 3
Gram negative
 Escherichia coli 17 ± 2 18 ± 2 18 ± 2 21 ± 2
 Salmonella typhi 17 ± 3 17 ± 2 18 ± 1 18 ± 1
 Vibrio cholerae 18 ± 1 16 ± 2 19 ± 2 19 ± 2
 Klebsiella pneumoniae 20 ± 2 18 ± 2 18 ± 1 21 ± 3
 Salmonella paratyphi 18 ± 2 19 ± 2 18 ± 2 20 ± 2
Table 2 Minimum inhibitory concentration (MIC) of  NN-
XIb-PLA2 and antibiotics in serial dilution method
The results are mean SD (n = 6)
G gentamycin, Cp chloramphenicol, Sm streptomycin
Microorganisms MIC (µg/ml)
NN‑PL‑XIb G Cp Sm
Gram positive
 Staphylococcus aureus 23.3 ± 3 20.8 ± 1 14.4 ± 2 13.6 ± 1
 Bacillus subtilis 25.1 ± 1 20.8 ± 3 14.4 ± 1 16.6 ± 1
Gram negative
 Escherichia coli 19.3 ± 3 23.8 ± 1 14.4 ± 2 14.6 ± 1
 Salmonella typhi 22.1 ± 3 18.8 ± 1 17.4 ± 2 13.6 ± 1
 Vibrio cholerae 21.3 ± 2 19.8 ± 3 14.4 ± 1 19.6 ± 1
 Klebsiella pneumoniae 26.1 ± 3 20.8 ± 1 14.4 ± 2 13.6 ± 1
 Salmonella paratyphi 21.4 ± 2 23.8 ± 1 14.4 ± 2 14.6 ± 1
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bactericidal activity (Paramo et al. 1998; Samy et al. 2012; 
de Oliveira Junior et al. 2013), emphasizing the fact that 
bactericidal activity is not associated with enzymatic 
activities. In relation to these observation, in our study 
it was observed that, when the protein was preincubated 
with p-BPB (an inhibitor of svPLA2 enzymatic activity) 
(Rudrammaji et  al. 2001), a significant decrease in anti-
bacterial activity was observed (Fig.  3), and complete 
abolition of antibacterial activity is observed (Table  3), 
indicating that their was no dissociation of enzymatic 
activity and bactericidal/antibacterial activity of NN-XIb-
PLA2. Furthermore, considering the homogenous nature 
of the protein with no associated other venom enzymatic 
activities (like L-amino-oxidase, proteases etc..) in the 
preparation (Data not shown), it may be concluded that 
the antibacterial activity of NN-XIb-PLA2 is depend-
ent upon the catalytic activity i.e. enzymatic membrane 
degradation effect. However other mechanisms can not 
be completely ruled out which may include the “fatal 
depolarization” of the bacterial membrane, creation of 
physical holes in the membrane, scrambling of normal 
distribution of lipids between the bilayer leaflets, dam-
age of critical intracellular targets after internalization 
of the peptide, and also by inhibition of macromolecu-
lar biosynthesis as observed in many of svPLA(2)s and/
or interacting with specific vital components inside the 
bacteria (Park et  al. 1998; Samy et  al. 2012; Sudarshan 
and Dhananjaya 2015). Agkistrodon piscivorus piscivorus 
PLA2s was shown to interact with lipopolysaccharide 
(LPS) and lipid A from different gram negative bacteria 
or with the lipoteichoic acid from Staphylococcus aureus, 
and is known to rely on a membrane-permeabilizing 
mechanism to exert its bactericidal effects (Shen and 
Cho 1995). Saikia et  al. (2012) recently demonstrated 
that the presence of a large number of PLA2-sensitive 
phospholipid domains/composition, and rather than 
only the phosphatidylcholine (PC) content of a particu-
lar membrane determine the extent of membrane dam-
age by a particular venom PLA2 enzyme. As observed in 















Fig. 2 Dose dependent indirect hemolytic activity of NN-XIb-PLA2. 
NN-XIA-PLA2 (0–3 µg) in 100 µl of phosphate-buffered Saline (PBS) 
was incubated with erythrocytes, egg yolk and PBS (1:1:8 v/v) for 
10 min at 37 °C. The released hemoglobin in the supernatant was 
measured by taking absorbance at 540 nm. The results shows ± SEM 




















Fig. 3 Bactericidal activity against different human pathogenic strains of NN-XIb-PLA2. NN-XIb-PLA2 (6 μg/ml) was preincubated with or without 
different concentration of p-BPB (6 μM) at 37 °C for 15 min and bactericidal activity was estimated in agar diffusion assay. The diameter of the clear 
zone was measured and plotted after subtracting the diameter of the well (5 mm). Results are mean ± SD for three independent assays each 
performed in triplicate
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inhibitory potency of NN-XIb-PLA2 on various bacterial 
species. However the protein being an acidic PLA2 (NN-
XIb-PLA2) seems to bring out its antimicrobial activity 
by acting upon the membrane and hydrolyze it through 
its enzymatic activity. From this study it seems that there 
is a strong correlation between catalytic activity and 
antimicrobial effects of NN-XIb-PLA2. However, other 
mechanisms can not be completely ruled out. Therefore, 
further studies of molecular mechanism of action of NN-
XIb-PLA2 bactericidal activities will be interesting to 
develop this as a therapeutic lead molecule for applica-
tion purpose.
Conclusion
This study indicates the potential bactericidal activities of 
NN-XIb-PLA2, a PLA2 of Naja naja venom. A significant 
decrease in antibacterial activity in presence of p-BPB 
(an inhibitor of PLA2 enzymatic activity) was observed, 
suggesting a correlation between enzymatic and anti-
bacterial activity. Also, it may pocess other properties 
that mimic the bactericibal/membrane permeability-
increasing protein. Thus these studies encourage further 
in dept study on molecular mechanisms of anti-bacterial 
properties and thereby help in development of this pro-
tein into therapeutic lead molecule for treating bacterial 
infections.
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